DIAB s.r.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At DIAB s.r.o. in Roznava, clinical research in cardiovascular diseases focuses on people with established or high-risk cardiovascular disease, including atherosclerotic cardiovascular disease and related complications. These studies are designed to test new ways to lower the risk of major heart and blood vessel events and to improve long-term protection for patients.
- Evaluating therapies aimed at reducing the risk of myocardial infarction, stroke, and other major cardiovascular events
- Studying treatments for patients with elevated lipoprotein(a) and established cardiovascular disease
- Assessing the effectiveness and safety of lipid-lowering approaches in adults at high cardiovascular risk
The site’s work also includes research on long-term safety and tolerability, helping clarify how these therapies may support better prevention and ongoing care in cardiovascular medicine.
Nutritional and Metabolic Diseases
Research in nutritional and metabolic diseases at this hospital clinic centers on type 2 diabetes mellitus, obesity, overweight, and severe hypertriglyceridemia. The trials explore new treatment options that may help with weight control, metabolic health, and related complications such as chronic kidney disease.
- Testing therapies for weight reduction in adults with overweight or obesity, including those living with type 2 diabetes
- Evaluating treatments for severe hypertriglyceridemia to improve lipid management
- Studying options that may slow chronic kidney disease progression and reduce albumin in the urine
Overall, the research aims to improve treatment effectiveness for common metabolic conditions while also addressing their impact on kidney and heart health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novartis Pharma AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in DIAB s.r.o.
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Jun 2026 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 3 | Unknown | 2023-05-17 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.